On July 9, 2004, DiagnoCure Inc., a biotechnology company specializing in the development, production and commercialization of diagnostic tests for the detection of cancers, completed a public offering of 5 million common shares in Canada and the US. The closing resulted in the gross proceeds of $23,750,000. National Bank Financial Inc. led the underwriting syndicate, which included Desjardins Securities Inc., Dundee Securities Corp. and Haywood Securities Inc.
DiagnoCure was represented by Philippe Leclerc (corporate finance) of McCarthy Tétrault, with the assistance of Philippe Fortier (corporate finance) and David Judson and Michael Smith on US securities matters.
The underwriters were represented by Shahir Guindi, Warren Katz, François Leblanc (corporate finance) and Karen Shaw (technology) of Osler, Hoskin & Harcourt.
DiagnoCure was represented by Philippe Leclerc (corporate finance) of McCarthy Tétrault, with the assistance of Philippe Fortier (corporate finance) and David Judson and Michael Smith on US securities matters.
The underwriters were represented by Shahir Guindi, Warren Katz, François Leblanc (corporate finance) and Karen Shaw (technology) of Osler, Hoskin & Harcourt.
